Skip to content

dr. Snauwaert Sylvia

Hematologie
contactgegevens
Geen artikels gevonden...
04/02/2023
Laboratoriumgeneeskunde

Alternative genetic alterations of MYC, BCL2, and/or BCL6 in high-grade B-cell lymphoma (HGBL) and diffuse large B-cell lymphoma (DLBCL): Can we identify different prognostic subgroups?

Genes Chromosomes Cancer. 2023;1–8 - PMID: 37897298dr. Devos Helenadr. Snauwaert Sylviadr. De Paepe Pascaledr. Emmerechts Jandr. Cauwelier Barbara
04/02/2023
Laboratoriumgeneeskunde

Breast Implant associated EBV-positive Diffuse Large B-cell Lymphoma: An underrecognized entity?

Diagn Pathol. 2023;18:52. - PMID: 37098615dr. Gieraerts Katriendr. Devos Helenadr. Snauwaert Sylviadr. De Paepe Pascaledr. Vanwalleghem Lievedr. Lesaffer Jan
01/08/2023
Laboratoriumgeneeskunde

Diagnostic utility of the lymphoid screening tube supplemented with TRBC1 for the assessment of T-cell clonality.

Int J Lab Hematol. 2023 Aug;45(4):496-505dr. Snauwaert Sylviadr. Emmerechts Jandr. sc. Nollet Friedeldr. Cauwelier Barbara
28/10/2023
Laboratoriumgeneeskunde

Alternative genetic alterations of MYC , BCL2 and/or BCL6 in high grade B-cell lymphoma (HGBL) and diffuse large B-cell lymphoma (DLBCL): can we identify different prognostic subgroups?

Genes, Chromosomes and Cancer. 2023 Oct 28. doi: 10.1002/gcc.23211. dr. Devos Helenadr. Snauwaert Sylviadr. De Paepe Pascaledr. Emmerechts Jandr. Cauwelier Barbara
25/04/2023
Anatomopathologie

Breast implant associated EBV-positive Diffuse Large B-cell lymphoma: an underrecognized entity?

Diagn Pathol. 2023 Apr 25;18(1):52. doi: 10.1186/s13000-023-01337-5.PMID: 37098615 Free PMC article. https://pubmed.ncbi.nlm.nih.gov/37098615/dr. Gieraerts Katriendr. Devos Helenadr. Snauwaert Sylviadr. Vanwalleghem Lievedr. Lesaffer Jan
28/10/2023
Hematologie

Alternative genetic alterations of MYC, BCL2, and/or BCL6 in high-grade B-cell lymphoma (HGBL) and diffuse large B-cell lymphoma (DLBCL): Can we identify different prognostic subgroups?

Genes Chromosomes Cancer. 2023 Oct 28. doi: 10.1002/gcc.23211. Online ahead of print. PMID: 37897298 dr. Devos Helenadr. Snauwaert Sylviadr. De Paepe Pascaledr. Emmerechts Jandr. Cauwelier Barbara
01/08/2023
Hematologie

Diagnostic utility of the lymphoid screening tube supplemented with TRBC1 for the assessment of T-cell clonality.

Int J Lab Hematol. 2023 Aug;45(4):496-505. doi: 10.1111/ijlh.14045. Epub 2023 Mar 1. PMID: 36856131 dr. Snauwaert Sylviadr. Emmerechts Jandr. sc. Nollet Friedeldr. Cauwelier Barbara
01/02/2023
Hematologie

Infectious diarrhea after allogeneic hematopoietic cell transplantation assessed by a multiplex polymerase chain reaction assay.

Int J Infect Dis. 2023 Feb;127:17-22. doi: 10.1016/j.ijid.2022.11.045. Epub 2022 Dec 6. PMID: 36481487 dr. Snauwaert Sylviadr. Van Praet Jensdr. Van Droogenbroeck Jandr. Selleslag Dominikdr. Lodewyck Tomdr. Reynders Marijkedr. Schauwvlieghe Alexander
25/04/2023
Hematologie

Breast implant associated EBV-positive Diffuse Large B-cell lymphoma: an underrecognized entity?

Diagn Pathol. 2023 Apr 25;18(1):52. doi: 10.1186/s13000-023-01337-5. PMID: 37098615 Free PMC article. dr. Gieraerts Katriendr. Devos Helenadr. Snauwaert Sylviadr. De Paepe Pascaledr. Vanwalleghem Lievedr. Lesaffer Jan
28/10/2023
Anatomopathologie

Alternative genetic alterations of MYC, BCL2, and/or BCL6 in high-grade B-cell lymphoma (HGBL) and diffuse large B-cell lymphoma (DLBCL): Can we identify different prognostic subgroups?

Genes Chromosomes Cancer. 2023 Oct 28. doi: 10.1002/gcc.23211. Online ahead of print.PMID: 37897298dr. Devos Helenadr. Snauwaert Sylviadr. De Paepe Pascaledr. Emmerechts Jandr. Cauwelier Barbara
25/04/2023
Anatomopathologie

Breast implant associated EBV-positive Diffuse Large B-cell lymphoma: an underrecognized entity?

2023 Apr 25;18(1):52. doi: 10.1186/s13000-023-01337-5.PMID: 37098615 Free PMC article.dr. Gieraerts Katriendr. Snauwaert Sylviadr. De Paepe Pascaledr. Lesaffer Jan
01/02/2023
Hematologie

Infectious diarrhea after allogeneic hematopoietic cell transplantation assessed by a multiplex polymerase chain reaction assay.

Int J Infect Dis. 2023 Feb;127:17-22. doi: 10.1016/j.ijid.2022.11.045. Epub 2022 Dec 6.PMID: 36481487 dr. Snauwaert Sylviadr. Van Praet Jensdr. Van Droogenbroeck Jandr. Selleslag Dominikdr. Lodewyck Tomdr. Reynders Marijkedr. Schauwvlieghe Alexander
06/12/2023
Hematologie

Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study.

Blood 2022 Apr 14;139(15):2338-2346. doi: 10.1182/blood.2021013526. -PMID: 34936697 DOI: 10.1182/blood.2021013526dr. Snauwaert Sylvia
06/12/2023
Hematologie

High total metabolic tumor volume at baseline predicts survival independent of response to therapy.

Blood. 2020 Apr 16;135(16):1396-1405. doi: 10.1182/blood.2019003526.PMID: 31978225 Free PMC article. Clinical Trial.dr. Snauwaert Sylvia
04/01/2020
Hematologie

Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study.

Br J Haematol. 2020 Apr;189(1):84-96. doi: 10.1111/bjh.16300. Epub 2019 Nov 8.PMID: 31702836 Free PMC article.dr. Snauwaert Sylvia
05/01/2020
Hematologie

TARP is an immunotherapeutic target in acute myeloid leukemia expressed in the leukemic stem cell compartment.

Haematologica. 2020 May;105(5):1306-1316. doi: 10.3324/haematol.2019.222612. Epub 2019 Aug 1.PMID: 31371409 Free PMC articledr. Snauwaert Sylvia
03/01/2019
Hematologie

Guidelines of the Belgian Hematology Society on the use of stem cell transplantation in lymphoproliferative diseases.

Belgian journal of hematology volume 10 issue 2 march 2019 p 69-79.dr. Snauwaert Sylvia
11/08/2019
Hematologie

Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study.

Br J Haematol. 2019 Nov 8. doi: 10.1111/bjh.16300. PMID: 31702836dr. Snauwaert Sylvia
08/01/2019
Hematologie

TARP is an immunotherapeutic target in acute myeloid leukemia expressed in the leukemic stem cell compartment.

Haematologica. 2019 Aug 1. pii: haematol.2019.222612. doi: 10.3324/haematol.2019.222612. PMID: 31371409dr. Snauwaert Sylvia
08/01/2019
Hematologie

Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.

Lancet Haematol. 2019 Aug;6(8):e429-e437. doi: 10.1016/S2352-3026(19)30089-4. Epub 2019 Jul 8. PMID: 31296423dr. Snauwaert Sylvia
01/01/2018
Inwendige Ziekten

Hodgkin’s lymphoma: Belgian Hematology Society guidelines in diagnosis, treatment and follow-up.

Belgian Journal of Hematology. 2018; 9; 214-224.dr. Snauwaert Sylviadr. De Wilde Vincent
02/01/2018
Inwendige Ziekten

Highlights in lymphoma.

Belgian Journal of Hematology. 2018 Feb; 9(1): 14-18.dr. Snauwaert Sylvia
Hematologie

Nationale BHS cursus voor hematologen in opleiding: peripheral T cell lymphoma and NK T cell lymphoma.

2023-03-18dr. Snauwaert Sylvia
Hematologie

Post-EHA event CLL first line therapy.

Brugge2023-07-04dr. Snauwaert Sylvia
Hematologie

BHS webinar: Mantle cell lymphoma and BTK-inhibitors.

Brugge2023-09-27dr. Snauwaert Sylvia
Hematologie

CAR-TEAM meeting: opleiding voor refererende centra rond patient journey CAR-T.

Brugge2023-11-09dr. Snauwaert Sylvia
Hematologie

Opleiding CAR-T therapie voor themadagen hemato verpleging.

Brugge2023-11-23dr. Snauwaert Sylvia
Hematologie

Opleiding CAR-T therapie voor themadagen IZ verpleging.

Brugge2023-11-14dr. Snauwaert Sylvia
Hematologie

Neuropathie, longinfecties en andere ernstige complicaties bij multiple myeloom en Waldenström.

dr. Snauwaert Sylvia
Hematologie

T-cell lymphoma.

Brussel2022-03-26dr. Snauwaert Sylvia
Hematologie

Oral Azacytidine in Patients with Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma: Final Analysis of the Oracle Phase III Study.

2022-01-01dr. Snauwaert Sylvia
Hematologie

Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Final Analysis of a Lysa Multicenter, Phase II Study. “the TOTAL Trial”.

2022-01-01dr. Snauwaert Sylvia
Hematologie

Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R2) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial.

2022-01-01dr. Snauwaert Sylvia
Hematologie

EFFECTIVENESS AND SAFETY OF IBRUTINIB IN WALDENSTRÖM’S MACROGLOBULINEMIA (WM) IN BELGIAN ROUTINE CLINICAL PRACTICE WITH A 3-YEAR FOLLOW-UP.

2022-01-01dr. Snauwaert Sylvia
Hematologie

Effectiveness and Safety of Ibrutinib in Patients with Mantle Cell Lymphoma (MCL) in Belgian Routine Clinical Practice: 3-Year Follow-up.

2022-01-01dr. Snauwaert Sylvia
Hematologie

EFFECTIVENESS AND SAFETY OF IBRUTINIB IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND MANTLE CELL LYMPHOMA (MCL) IN BELGIAN ROUTINE CLINICAL PRACTICE WITH A 3-YEAR FOLLOW-UP.

Poster at virtual EHA 20212021-09-06dr. Snauwaert Sylvia
Hematologie

Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Results of a Lysa Multicenter, Phase II Study.

ASH 20202020-01-01dr. Snauwaert Sylvia
Hematologie

Final Analysis of the International Double-Blind Randomized Phase III Study of Lenalidomide Maintenance in Elderly Patients with DLBCL in Response after R-CHOP.

Poster at ASH;2020-12-06dr. Snauwaert Sylvia
Hematologie

TARP AS IMMUNOTHERAPEUTIC TARGET IN AML EXPRESSED IN THE LSC COMPARTMENT.

EHA Library. Depreter B. 06/14/19; 265994; PF204. Poster at EHA 2019.2019-01-01dr. Snauwaert Sylvia
Hematologie

Impact of Total Metabolic Tumor Volume at Baseline in the Remarc Study.

Poster At ASH 20182018-01-01dr. Snauwaert Sylvia
Hematologie

Galapagos project: samenwerking met reumatologie: Bloody issues in RA. Hematologische problemen bij patiënten met reumatoïde arthritis.

2020-12-14dr. Snauwaert Sylvia
Hematologie

Urgenties in de hematologie.

2020-10-07dr. Snauwaert Sylvia
Hematologie

Young hematology education: How to onboard a CLL patient in first line treatment?

2020-11-16dr. Snauwaert Sylvia
Hematologie

Waldenström’s macroglobulinemia and renal insufficiency: a case report.

2020-02-14dr. Snauwaert Sylvia
Hematologie

Clinical Outcomes with Single-Agent ibrutinib for relapsed/refractory mantle cell lymphoma: IA of the Belgian Ibrutinib Real-World Data (BiRD) Study.

dr. Snauwaert Sylvia
Hematologie

Effectiveness and safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: IA of the Belgian Ibrutinib Real-World Data (BiRD) Study.

dr. Snauwaert Sylvia
Inwendige Ziekten

20th Post-ASH Meeting.

Brusseldr. Snauwaert Sylvia